CTLA-4 is a T cell surface molecule that binds to the costimulatory molecul
es CD80 and CD86 on antigen-presenting cells and downregulates T cell funct
ion. Therefore, we wanted to test whether antigen-specific activated T cell
s could be inhibited through directed CTLA-4 signaling using a bispecific a
ntibody (BiAb) capable of simultaneously binding to CTLA-4 and a tissue-spe
cific antigen. The BiAb was prepared by linking two separate monoclonal ant
ibodies against CTLA-4 and the thyroid-stimulating hormone receptor (TSHR).
The mouse B cell lymphoma line M12 (H2(d)) was used to induce alloreactive
T cells in CBA/J mice (H2(k)); M12 cells stably transfected with the cDNA
encoding murine TSHR (mM12) were used to restimulate the alloresponse in vi
tro. Results of assays for in vitro T cell proliferation, IL-2 production,
and cytoxicity in the presence of BiAb demonstrated that the BiAb could inh
ibit the T cell alloresponse when stimulated with mM12 cells but not with M
12 cells. This effect was dependent on binding of TSHR-bound BiAb to CTLA-4
, since the addition of soluble CTLA-4-Ig blocked the inhibitory effect. In
jection of mM12 cells, along with the BiAb, not with antibodies against TSH
R or CTLA-4 either separately or together, into CBA/J mice (H2(k)) downregu
lated alloreactive T cell responses. Our study demonstrated that the presen
ce of CTLA-4 signaling molecules on the surface of target cells can protect
those cells from immune attack by antigen-specific T cells and suggested t
hat a similar approach could have potential therapeutic value in transplant
rejection and tissue-specific autoimmune diseases. (C) 2001 Academic Press
.